

## **A Novel Biomarker for Diagnosis of Ulcerative Colitis and Colon Cancer**

### **Background**

Tropomyosins are microfilament-associated proteins found in all eukaryotes and have been implicated in autoimmune diseases such as ulcerative colitis. To date, eight different isoforms (hTM1, hTM2, hTM3, hTMs $\alpha$ , hTM5a, hTM5b, hTM4, and hTM5) have been identified. Although anti-tropomyosin autoantibodies have been detected in the sera of patients with ulcerative colitis, the autoantigen triggering the autoantibody response has not been definitively identified. Previous studies at UMDNJ have identified hTM5 as the predominant immunogen in ulcerative colitis patients.

Ulcerative colitis is difficult to diagnose because its symptoms are similar to other intestinal disorders. Furthermore, about 5% of patients with ulcerative colitis develop colon cancer. **Thus, the identification of the autoantigen(s), in particular, the specific isoform of Tropomyosin and the specific epitope(s) that trigger ulcerative colitis and colon related diseases and dysfunction would be therapeutically beneficial.**

### **Description of the Technology**

A new isoform of tropomyosin, named TC22, that predominates in human colon carcinoma has been identified and completely sequenced. Monoclonal antibodies, TC22-2, TC22-4, TC22-6 and TC22-7, specific for this distinctive protein have been generated.

A significantly large percentage (83%) of colon cancer tissues obtained from colon cancer patients showed strong reactivity with TC22-4 monoclonal antibody compared with normal colon epithelial cells or normal colonic mucosa tissue from patients with Crohn's disease. Further, the amount of the TC22 protein was also elevated in ulcerative colitis tissues.

Studies with GFP-TC22 revealed a weak interaction of the TC22 protein with actin filaments. During mitosis, the alignment of mitotic spindle is guided by strength of the actin filament-tropomyosin interaction thereby influencing cellular proliferation. The elevated expression of TC22 isoform in colon cancer cells and its abnormal interaction with actin filaments implicate a role for TC22 protein in cellular proliferation and cancer. Thus, this novel biomarker can be used for screening and detection of patients at risk of developing colon cancer and other colon related diseases, and ulcerative colitis.

### **Deliverables**

- TC22 clones, GFP-TC22 constructs, and eukaryotic expression systems
- TC22-2 (IgM), TC22-4 (IgG<sub>1</sub>), TC22-6 (IgM) and TC22-7 (IgM) monoclonal antibodies

### **Advantages**

- Surgery is the only cure for ulcerative colitis. The availability of a monoclonal antibody enables the design of simple and inexpensive diagnostic tests for the early detection and prevention of colon dysfunction and diseases.
- Current diagnostic methods involve endoscopic or colonoscopic procedures that are

expensive and painful. Patients with inflammatory bowel disease for a prolonged period of time are recommended for colonoscopic identification of precancerous dysplasia.

File RWJ 01-08/Das

### **Applications**

- . • To develop in vitro diagnostics for ulcerative colitis and colon cancer
- . • To develop assays for the screening of novel agents capable of modulating the activity of TC22 for therapeutic applications
- . • For research use to further the scientific advancement in the area of colon cancer and ulcerative colitis.
- . • For selecting patients for enrolment in clinical trials.

### **Patent Status**

- . • United States and PCT patent applications filed.
- . • PCT application published on 01/30/2003 (Publication No.: WO 03/007890 A2)

### **Licensing Opportunity**

- This technology is available for non-exclusive or exclusive license.

### **Contact**

Peter Golikov, MS, MBA  
Director, Ventures and Licensing  
University of Medicine and Dentistry of New Jersey  
335 George Street  
New Brunswick, NJ 08901  
Direct Phone: (732)-235-9355  
Main Office Phone: (732)-235-9350  
Facsimile: (732)-235-9358  
golikope@umdnj.edu

File RWJ 01-08/Das